All Insights

LP Diligence & Workflow

A Practical Guide to Private Equity Secondaries for LPs: GP vs LP, GP-Leds, and What Allocators Actually Underwrite

The secondary market is no longer a clearing house for distressed LP interests. It has become a core liquidity and portfolio-construction tool - and a separate underwriting problem from primary commitments.

Matthew S. · Founder, Allocator Desk · June 2026 · 14 min read

The private equity secondary market crossed $160B in 2024 and is on pace to set a new record this year. What used to be a quiet corner where LPs occasionally offloaded unwanted tail-end interests is now a structural part of how institutional portfolios are managed - and an asset class in its own right, with dedicated funds, dedicated diligence, and a vocabulary that confuses almost everyone outside it.

The vocabulary is where most newcomers stumble. "LP-led" and "GP-led" sound like minor distinctions; they are entirely different transactions with different risks, different counterparties, and different reasons LPs participate. This guide walks through both, the underlying GP versus LP relationship that makes them possible, and the questions a serious allocator asks before either selling into or buying out of a secondary deal.

First principles: what GP vs LP actually means

A private equity fund has two sides. The General Partner (GP) is the management firm - the people sourcing deals, executing the strategy, and earning carried interest. The Limited Partners (LPs) are the institutional investors who commit the capital - pensions, endowments, foundations, sovereign wealth funds, insurance companies, and family offices.

The relationship is governed by a Limited Partnership Agreement (LPA) and is structurally asymmetric. The GP runs the fund and makes every investment decision; LPs have almost no day-to-day control. In exchange for that loss of control, LPs get limited liability - their downside is capped at their committed capital - and the GP takes on the operational, legal, and reputational risk of running the firm.

This asymmetry is the entire reason secondaries exist. An LP who decides three years into a ten-year fund that the commitment no longer fits their portfolio cannot vote to wind it down. They can only do one of two things: hold to maturity, or sell their LP interest to someone else. That sale is a secondary transaction.

For more on how that LPA actually allocates economics between the two sides, see our explainers on carried interest and the distribution waterfall - both of which carry over, unchanged, when a secondary buyer steps into an LP's shoes.

The two transaction types, clearly separated

Secondaries split into two families that share little beyond the name.

LP-led secondaries

An LP-led deal is exactly what it sounds like: a Limited Partner sells their stake in one or more funds to a buyer (typically a dedicated secondaries fund). The GP is informed and must consent to the transfer, but is otherwise a bystander. The fund itself does not change. Only the name on the LP register does.

LPs sell for portfolio reasons, not investment reasons:

• **Liquidity** - meeting a capital call elsewhere, funding distributions, or freeing up cash for a new strategy.
• **Pacing and over-allocation** - the denominator effect (public markets fall, private NAV doesn't, so private allocation drifts above target).
• **Portfolio cleanup** - tail-end funds, non-strategic GP relationships, or commitments inherited from a predecessor team.
• **Re-underwriting** - the LP has lost conviction in the GP and wants out before the next vintage decision forces the issue.

Pricing is expressed as a percentage of NAV. A clean buyout fund of a top-tier GP may trade at par or a small premium; a tail-end venture fund with concentration risk and uncertain reserves may trade at 60 to 80 cents on the dollar. The discount is the buyer's compensation for risk, illiquidity, and the GP-blind nature of the underwriting (they often cannot speak to the GP about specific portfolio companies before bidding).

GP-led secondaries

A GP-led is a fundamentally different animal. Here the GP initiates the transaction, typically because they want to extend their hold on one or more high-conviction portfolio companies beyond the life of the original fund. The most common structure is a continuation vehicle (CV): a new fund, managed by the same GP, that buys specified assets out of the old fund. Existing LPs are given a choice - take cash for their pro-rata share at the deal price, or roll their interest into the new vehicle and continue holding the assets.

GP-leds went from roughly a tenth of the secondaries market a decade ago to roughly half today. They exist because the alternative - forced sales at the end of a fund's life - has destroyed value in too many otherwise healthy assets. A great company that needs three more years and an additional $200M to compound through its next chapter should not be sold to a strategic at year ten just because the fund's term is up.

But GP-leds also concentrate conflicts of interest in a way LP-leds never do. The GP is simultaneously the seller (representing old-fund LPs) and the buyer (managing the new vehicle and earning fresh fees and carry on it). The price they set determines how much old-fund LPs receive and how much upside transfers to the new vehicle's investors. Independent fairness opinions, LPAC consent, and competitive price discovery exist precisely because the GP cannot credibly negotiate against themselves.

What are GP-led secondaries, exactly?

A GP-led secondary is any transaction where the GP, not an LP, drives the liquidity event. The continuation vehicle is the dominant form, but it is not the only one:

• **Single-asset CV** - the GP moves one trophy asset (often the fund's largest position) into a new vehicle. These are the most scrutinized deals because the conflict is most visible.
• **Multi-asset CV** - a basket of three to ten assets is moved. Diversification mutes the single-asset concentration concern but raises questions about which assets were included and why.
• **Strip sales** - the GP sells a minority slice of multiple fund positions to a buyer, with proceeds distributed to LPs. The fund continues, the GP keeps management.
• **Tender offers** - the GP arranges for a third-party buyer to offer existing LPs liquidity at a set price, without restructuring the fund.

The common thread is that the GP is choosing both the timing and the price. That is the structural reason GP-leds require a different diligence framework than primary commitments - and a different framework again from LP-led secondaries.

Why LPs participate (both sides)

The market exists because secondaries solve real problems on both sides of the trade.

For sellers:

• Convert paper NAV into actual cash without waiting for the fund's natural distribution schedule.
• Rebalance allocations without selling public assets at inopportune prices.
• Exit GP relationships that no longer fit the program without the awkwardness of declining a re-up call.
• Manage [commitment pacing](/insights/commitment-pacing-for-lps-how-to-build-a-pacing-model) when prior vintages are returning capital more slowly than the model assumed.

For buyers (whether secondaries funds or LPs buying directly):

• Shorter J-curve - the fund is already invested, so distributions begin sooner.
• Better visibility - you can see the portfolio companies that exist today rather than underwriting a blind pool.
• Mathematical entry discount - paying 85 cents on a NAV the GP has already marked is a real margin of safety, assuming the marks are credible.
• Vintage diversification - one secondary purchase can deliver exposure to multiple fund years simultaneously.

For GPs running CVs:

• Hold winners longer instead of force-selling on a fund clock.
• Reset fees and carry on the rolled portion (a real economic upside, and the source of much of the conflict).
• Provide optionality to old-fund LPs without surprising them with an unwanted multi-year extension.

<aside><strong>Secondary diligence - the questions that separate good deals from bad</strong><p>LP-led purchases: Are the marks current and credible? What is the unfunded commitment and how will it be called? Who else is in the LP register and could a co-investor block transfer? What is the reserve adequacy for follow-ons? GP-led participations: Was there a competitive process and an independent fairness opinion? What does the LPAC vote tell you? Is the price set against current NAV or a stale mark? How are fees and carry reset on the rolled portion - and does the math actually favor rolling over taking cash? Why is the GP selling this asset to themselves rather than to a strategic? Either side: Are you underwriting a key person who is still at the firm, or one who is on their way out?</p></aside>

How GP-leds are actually underwritten by LPs

For an LP being offered a roll-or-sell choice in a GP-led, the decision is not "is this a good company" - the GP wouldn't be running the deal if they didn't believe that. The decision is "is this price fair, and is rolling better than taking cash and redeploying."

A defensible process:

1. Read the fairness opinion critically. It tells you the price is within a defensible range, not that it is the right price. Look at the comparables used, the discount rates applied, and whether the opinion considered illiquidity discounts appropriate for the holding period.

2. Check the process. Was the asset shown to other buyers? How many bidders were there? A GP-led that was never market-tested is structurally weaker than one that beat external bids.

3. Read the LPAC vote. The LPAC sees diligence you do not. A unanimous LPAC approval is a signal; a split or contentious vote is a louder one.

4. Run the rollover math. What is the new fee and carry structure? What is the implied IRR if the asset hits the GP's base case, and what is it if the GP misses? Does rolling outperform taking cash and redeploying it elsewhere at your portfolio's expected return?

5. Look at the GP's incentives. A GP rolling significant personal capital into the CV at the same price LPs are being offered is showing alignment. A GP taking only the management fee and a fresh carry while LPs absorb the risk is showing something else.

The single best discipline is to write down, in the IC memo, what you would need to believe to take each option - sell, roll, or do nothing - and then ask which set of beliefs is most defensible given the evidence. Capturing that reasoning is exactly the kind of decision the audit trail discussion was written about: GP-leds are precisely the moments LPs will want to revisit later.

Pricing and the discount-to-NAV question

Secondaries pricing is conventionally expressed as a percentage of the GP's reported NAV. The headline number hides most of the substance.

A 90 percent of NAV price on a buyout fund and a 90 percent of NAV price on a venture fund are not comparable transactions. Venture marks are more subjective, more concentrated in a few positions, and more sensitive to a single down round. Buyout marks tend to be more stable but can be staler. Real estate and infrastructure marks behave differently again.

The credible questions are:

• **What is the reference date for NAV?** A "90 percent of June 30 NAV" price means something different in October than in July.
• **What has happened to the portfolio since the reference NAV?** Major write-ups or write-downs in interim months are not in the price.
• **What unfunded commitment am I taking on?** A discount on NAV that comes with a large unfunded number is a much smaller real discount.
• **What is the implied internal rate of return at this price?** Convert the price into the actual return assumption it implies; the percentage of NAV is a heuristic, not the answer.

Red flags - on both sides of a trade

A few patterns that should slow any secondary deal down:

• An LP-led seller who will not explain why they are selling, or whose explanation does not match the file (e.g. "portfolio cleanup" for what is actually their best-performing position).
• A GP-led with no competitive process, no fairness opinion, or an LPAC vote that was rushed through with limited information.
• Marks that have not been updated for two or more quarters in a fast-moving sector.
• A secondaries buyer who refuses to share their diligence pack with co-investors or LPAC observers.
• An offering memorandum that buries the fee reset, carry waterfall, or hurdle changes in fine print.

None of these is fatal alone. Two together is a pattern, and pattern is what matters when the underlying assets are illiquid and the price is being set by interested parties.

The market is maturing - and so should the diligence

A decade ago, secondaries diligence was often improvised. Today, the largest LPs run secondaries as a dedicated allocation with its own pacing model, its own coverage assignments, and its own decision templates. The GP-led half of the market in particular has institutionalized fast: independent fairness opinions are now standard, LPAC processes are more formal, and the better GPs market-test their continuation vehicles competitively before pricing them.

For LPs new to the asset class, the practical path is the same one that works for any private market: build the diligence checklist once, run it consistently, capture every commitment decision in writing, and revisit the file two and four years later to see what you got right and what you got wrong. The asset class rewards process more than it rewards heroics. The secondaries that destroy value almost always look, in retrospect, like deals that were under-diligenced for excitement reasons - "we have to move fast, the price is good, the GP needs an answer by Friday" - rather than deals that were genuinely well-priced and well-structured.

Treat them as their own underwriting problem, not a faster path to primary exposure, and the market is genuinely one of the more interesting opportunities in institutional portfolios today.

Topics

• Secondaries
• GP-led
• LP Structures
• Continuation Vehicles
• Portfolio Construction